Efficacy and Safety of Endostar Combined with Cisplatin in Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 LIUZi-li ¹ ,  HUANGLi-nian ² , WANGBin ¹ , LIUJi-zhu ¹ , LIUWei-wei ¹

1. Department of Respiratory Diseases, Huaibei Miners General Hospital, Huaibei 235000, China;
2. Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China;

Corresponding author：

HUANGLi-nian, Email: bbmchln@126.com

Keywords：

Endostar; Cisplatin; Non-small cell lung cancer; Malignant pleural effusion; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20160086

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of intrapleural injection of endostar combined with cisplatin in treatment of non-small cell lung cancer (NSCLC) with malignant pleural effusion. Methods Databases including PubMed, The Cochrane Library (Issue 2, 2016), EMbase, Web of Science, CNKI, VIP and WanFang Data were searched to collect randomized controlled trials (RCTs) about endostar combined with cisplatin for NSCLC with malignant pleural effusion from inception to February 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was performed by using RevMan 5.3 software. Results A total of 10 RCTs involving 610 patients were finally included. The results of meta-analysis showed that: The overall response rate and the improvement rate of quality of life in the endostar combined with cisplatin group were higher than that of the cisplatin alone group (RR=1.71, 95%CI 1.49 to 1.95, P<0.00001; RR=1.68, 95%CI 1.44 to 1.96, P<0.00001, respectively). However, There were no significant differences between two groups in incidence of gastrointestinal reaction, incidence of leucopenia and incidence of thrombocytopenia (all P values>0.05). Conclusion Compared with cisplatin, intrapleural injection of endostar combined with cisplatin can improve the overall response rate and improve the quality of life of NSCLC patients with malignant pleural effusion. Due to the limited quality and quantity of included studies, more high quality studies are needed to verify the above conclusion.

Citation： LIUZi-li, HUANGLi-nian, WANGBin, LIUJi-zhu, LIUWei-wei. Efficacy and Safety of Endostar Combined with Cisplatin in Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2016, 16(5): 557-563. doi: 10.7507/1672-2531.20160086 Copy

1.	Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin, 2014, 64(1): 9-29.
2.	Shi SB, Ma TH, Li CH, et al. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori, 2012, 98(3): 314-319.
3.	段春霞, 梁晓光, 张志强. 恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效分析. 包头医学院学报, 2015, 31(2): 45-46.
4.	郑勤红, 胡伟, 廖小方, 等. 顺铂序贯恩度与单纯顺铂胸腔内灌注治疗恶性胸腔积液的临床对照研究. 肿瘤学杂志, 2013, 19(5): 386-389.
5.	Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org.
6.	刘欣, 王丽萍. 重组人血管内皮抑制素联合顺铂腔内化疗治疗非小细胞肺癌合并恶性胸腔积液临床观察. 肿瘤基础与临床, 2012, 25(3): 233-235.
7.	刘维, 哈敏文, 殷南昌, 等. 恩度联合顺铂胸腔内注射治疗非小细胞肺癌恶性胸腔积液临床研究. 山东医药, 2010, 50(8): 79-80.
8.	岳国军, 柏玉举, 马虎, 等. 顺铂联合恩度治疗非小细胞肺癌血性胸腔积液的疗效和安全性分析. 现代诊断与治疗, 2014, 25(11): 2478-2480.
9.	李文燕. 恩度胸腔内灌注治疗恶性胸腔积液疗效观察. 医药论坛杂志, 2011, 32(7): 170-171.
10.	杨勇, 林润英, 曹官铭. 恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液近远期疗效. 中国药业, 2013, 22(19): 21-22.
11.	沈清, 顾爱琴, 武建毅, 等. 重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液疗效观察. 实用临床医药杂志, 2012, 16(5): 29-31.
12.	涂建仁, 黄淑娟, 王美鑑. 重组人血管内皮抑制素联合顺铂胸腔灌注治疗晚期非小细胞肺癌恶性胸腔积液的临床疗效. 实用癌症杂志, 2014, 29(12): 1592-1594.
13.	陈洁, 苟淑萍, 栾文革. 重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效及对VEGF、HIF-1α、肿瘤标志物的影响. 临床和实验医学杂志, 2014, 13(21): 1778-1780.
14.	黄柬. 恩度联合顺铂胸腔内灌注治疗恶性胸腔积液疗效观察. 实用临床医药杂志, 2010, 14(7): 63-64.
15.	黄莉. 恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床观察. 吉林医学, 2014, 35(19): 4308-4309.
16.	何文杰, 江波, 李佳. 中心静脉导管闭式引流联合白细胞介素2腔内灌注在晚期肺癌并恶性胸腔积液中的应用. 重庆医学, 2013, 42(4): 445-447.
17.	徐继平, 周蕾, 杨卫兵. 恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液研究进展. 大连医科大学学报, 2015, 37(1): 89-92.
18.	吴凯, 卢慧宇, 段德军. 恩度联合顺铂胸腔内注射治疗非小细胞肺癌恶性胸腔积液临床观察. 临床肺科杂志, 2012, 17(1): 107-108.
19.	Folkman J. Anti-angiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 2006, 312(5): 594-607.
20.	王金万, 孙燕, 刘永煜, 等. 重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究. 中国肺癌杂志, 2005, 8(4): 283-290.
21.	Zhao WY, Chen DY, Chen JH, et al. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys, 2014, 70(1): 623-628.
22.	Wu Y, Yang L, Hu B, et al. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs, 2005, 16(5): 551-557.
23.	Ma X, Yao Y, Yuan D, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One, 2012, 7(12): e53449.
24.	Fan J, DU J, Wu J, et al. Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma. Oncol Lett, 2015, 9(2): 822-828.

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin, 2014, 64(1): 9-29.
2. Shi SB, Ma TH, Li CH, et al. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori, 2012, 98(3): 314-319.
3. 段春霞, 梁晓光, 张志强. 恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效分析. 包头医学院学报, 2015, 31(2): 45-46.
4. 郑勤红, 胡伟, 廖小方, 等. 顺铂序贯恩度与单纯顺铂胸腔内灌注治疗恶性胸腔积液的临床对照研究. 肿瘤学杂志, 2013, 19(5): 386-389.
5. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org.
6. 刘欣, 王丽萍. 重组人血管内皮抑制素联合顺铂腔内化疗治疗非小细胞肺癌合并恶性胸腔积液临床观察. 肿瘤基础与临床, 2012, 25(3): 233-235.
7. 刘维, 哈敏文, 殷南昌, 等. 恩度联合顺铂胸腔内注射治疗非小细胞肺癌恶性胸腔积液临床研究. 山东医药, 2010, 50(8): 79-80.
8. 岳国军, 柏玉举, 马虎, 等. 顺铂联合恩度治疗非小细胞肺癌血性胸腔积液的疗效和安全性分析. 现代诊断与治疗, 2014, 25(11): 2478-2480.
9. 李文燕. 恩度胸腔内灌注治疗恶性胸腔积液疗效观察. 医药论坛杂志, 2011, 32(7): 170-171.
10. 杨勇, 林润英, 曹官铭. 恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液近远期疗效. 中国药业, 2013, 22(19): 21-22.
11. 沈清, 顾爱琴, 武建毅, 等. 重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液疗效观察. 实用临床医药杂志, 2012, 16(5): 29-31.
12. 涂建仁, 黄淑娟, 王美鑑. 重组人血管内皮抑制素联合顺铂胸腔灌注治疗晚期非小细胞肺癌恶性胸腔积液的临床疗效. 实用癌症杂志, 2014, 29(12): 1592-1594.
13. 陈洁, 苟淑萍, 栾文革. 重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效及对VEGF、HIF-1α、肿瘤标志物的影响. 临床和实验医学杂志, 2014, 13(21): 1778-1780.
14. 黄柬. 恩度联合顺铂胸腔内灌注治疗恶性胸腔积液疗效观察. 实用临床医药杂志, 2010, 14(7): 63-64.
15. 黄莉. 恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床观察. 吉林医学, 2014, 35(19): 4308-4309.
16. 何文杰, 江波, 李佳. 中心静脉导管闭式引流联合白细胞介素2腔内灌注在晚期肺癌并恶性胸腔积液中的应用. 重庆医学, 2013, 42(4): 445-447.
17. 徐继平, 周蕾, 杨卫兵. 恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液研究进展. 大连医科大学学报, 2015, 37(1): 89-92.
18. 吴凯, 卢慧宇, 段德军. 恩度联合顺铂胸腔内注射治疗非小细胞肺癌恶性胸腔积液临床观察. 临床肺科杂志, 2012, 17(1): 107-108.
19. Folkman J. Anti-angiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 2006, 312(5): 594-607.
20. 王金万, 孙燕, 刘永煜, 等. 重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究. 中国肺癌杂志, 2005, 8(4): 283-290.
21. Zhao WY, Chen DY, Chen JH, et al. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys, 2014, 70(1): 623-628.
22. Wu Y, Yang L, Hu B, et al. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs, 2005, 16(5): 551-557.
23. Ma X, Yao Y, Yuan D, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One, 2012, 7(12): e53449.
24. Fan J, DU J, Wu J, et al. Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma. Oncol Lett, 2015, 9(2): 822-828.

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Endostar Combined with Cisplatin in Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content